Location History:
- Osaka, JP (2000)
- Yawata, JP (2002)
Company Filing History:
Years Active: 2000-2002
Title: **Noriyuki Kunou: Innovator in Ophthalmic Treatments from Yawata, Japan**
Introduction
Noriyuki Kunou is a notable inventor based in Yawata, Japan, recognized for his contributions to the field of ophthalmology. With two patents to his name, Kunou has demonstrated a commitment to advancing innovative treatments for vitreoretinal diseases.
Latest Patents
Among his latest inventions is a groundbreaking scleral plug made from a specific blend of polylactic acids. This scleral plug is designed to release medication in precise amounts, aiming to treat or prevent vitreoretinal diseases. The formulation consists of a high-molecular weight polylactic acid with a molecular weight of 40,000 or higher and a low-molecular weight variant with a molecular weight of 40,000 or lower. The ideal blending ratio ranges from 90/10 to 50/50, with the most effective being 80/20. Additionally, Kunou's patent includes an aqueous ophthalmic solution featuring apafant as its active ingredient, showcasing his dedication to developing effective treatments for ocular conditions.
Career Highlights
Kunou's work is primarily associated with Santen Pharmaceutical Co., Ltd., a leading company in the field of ophthalmic pharmaceuticals. His innovative approach and technical expertise have contributed significantly to the development of existing and new products aimed at improving patient outcomes.
Collaborations
Throughout his career, Kunou has collaborated with talented individuals such as Yuichiro Ogura and Atsutoshi Ota. These partnerships have played a vital role in fostering creativity and pushing the boundaries of research within the pharmaceutical industry.
Conclusion
Noriyuki Kunou stands out as an important figure in the innovation of ophthalmic treatments. His latest patents not only reflect his ingenuity but also his commitment to addressing significant medical challenges in the field. As he continues to work with Santen Pharmaceutical Co., Ltd. and fellow innovators, the future of ocular health looks promising.